Sunday, August 14, 2022
HomePress ReleaseEIN PresswireGlobal Oncology Preclinical Drug Intelligence 2022 - World's Largest Active Resource for...

Global Oncology Preclinical Drug Intelligence 2022 – World's Largest Active Resource for Decision Making


Global Distribution of 1200 Active Early Stage Drug Developers Covered inside Report

Oncology Preclinical Stage Drug Developers Present in Europe, Asia and United States

Oncology Preclinical Stage Drug Developers Present in Europe, Asia and United States

Global Oncology Early Stage Drug Intelligence Report 2022

Global Oncology Early Stage Drug Intelligence Report 2022

First Report to provide Extensive Insights on 1200+ Active Early Stage Oncology Companies developing over 1400+ New Drug Molecules Targeting Cancer

Specially designed to identify early stage researchers with new ideas capable of changing the face of drug discovery.”

— Amit Gupta – Editor

NEW DELHI, DELHI, INDIA, July 12, 2022 /EINPresswire.com/ — As per OmicsX records, each year globally approximately 400 new oncology targeting companies are established with new ideas to develop new molecules against cancer. Due to the large number and global distribution, it is quite difficult for market analysts and business development professionals to identify the growing number of active drug developers and track their technologies and business activities on routine basis.

Global Oncology Preclinical Stage Drug Intelligence Report 2022, covers largest set of authentic early stage oncology drug developers worldwide with their technology and early stage molecules available for partnering and is a perfect tool to identify new partnering leads.

Report for the first time identifies and profiles 1200 Active Early Stage Cancer Drug Development companies from 33 countries worldwide, developing 1400+ cancer-targeting drugs. It evaluates individual company’s technology, cancer indications drug development pipeline & analysis, drug targets information, Key Management Social and Business Contacts details and thus creates immense authentic knowledge base on hundreds of emerging proprietary technologies, M&A deals and partnering occurring in early stage cancer drug discovery domain in recent years.

KEY HIGHLIGHTS –

Report covers Entrepreneurs established in last few years with valid funding and clear demarked pipeline with Individual’s Technology, Pipeline, Drug Targets, Management, Funding and Partnering capabilities.

Complete Insights on Single Platform – Drug Developers, Emerging Technologies, Molecules, Targets, Mechanism of Action, Partnering Activities, Key Managements Social and Business Contacts.

Best Selling Product since more than a decade, and is developed through years of continues & dedicated team work.

Economic & User Friendly Option in compare with any other similar available market solution.

Report comes with Complete Free after sales Support and Further Report Customization Options with regular intelligence updates for next one year.

INSIDE REPORT –

Complete Prebuild Intelligence (All in Single Report)

Small Molecule : Kinase Inhibitors (122 Preclinical Stage Companies).

Small Molecule : Proteolysis Targeting Chimera (PROTACs) (29 Preclinical Stage Companies).

Small Molecule : RNA Targeting Therapeutics (43 Preclinical Stage Companies).

Nanoparticles / Nanotechnology based Cancer Targeting Drugs (61 Preclinical Stage Companies).

Cellular Therapy: T Cell/CAR-T/CAR-NK & other Cell based Therapies (125 Preclinical Stage Companies).

Oncolytic Viruses Pipeline in Early Stage Development (35 Preclinical Stage Companies).

Monoclonal Antibodies Pipeline in Early Stage Development. (162 Preclinical Stage Companies)

Bi-Specific & Multi Specific Antibodies pipeline in Early Stage Development (66 Preclinical Stage Companies).

Antibody Drug Conjugates Pipeline in Early Stage Development (62 Preclinical Stage Companies).

Cancer Vaccines Pipeline in Early Stage Development (80 Preclinical Stage Companies)

Exosome & Micro vesicles based Cancer Targeting Drugs (17 Preclinical Stage Companies).

Microbiome based Cancer Targeting Drugs (15 Preclinical Stage Companies).

Largest set of authentic early stage oncology drug developers worldwide with early stage molecules available for partnering and is a perfect tool to identify new partnering leads.

INDEX – Active Preclinical Stage Onco Drug Developers Included in Report (Alphabetically)

1E Therapeutics Ltd.

1st Biotherapeutics Inc.

20n Bio, Inc.

21st Century Therapeutics, Inc.

2A Pharma AB

3T Biosciences

4C Biomed, Inc

858 Therapeutics, Inc

A2 Biotherapeutics, Inc

A2A Pharmaceuticals

A2i Therapeutics Ltd

A6 Pharmaceuticals

Aakha Biologics, Inc

Aarvik Therapeutics, Inc

Aavocyte Inc.

Ab Therapeutics, Inc.

Abalone Bio, Inc.

Abalos Therapeutics

ABBA Therapeutics AG

AbClon Inc.

Abcuro, Inc.

Abera Bioscience AB

Abilita Bio, Inc.

Abintus Bio, Inc.

AbLeads

Abologix Sàrl

Abound Bio, Inc.

Abpro Therapeutics

AbSano B.V.

Absolve Therapeutics, Inc.

AbTis Co, Ltd.

Abzyme Therapeutics, LLC

AC BioScience SA

AcadeMab Biomedical Inc.

Accent Therapeutics

Accuronix Therapeutics

Aceragen, Inc.

Actavalon

Actinobac Biomed Inc

ActoKine Therapeutics, Inc.

Actym Therapeutics

Adamed Pharma S.A.

Adanate, Inc.

Adaptive Biotechnologies Corp.

ADCendo ApS

Adcentrx Therapeutics, Inc.

AdCure Bio LLC

Adecto Pharmaceuticals, Inc.

Adendra Therapeutics

AdoRx Therapeutics

& 1151 more Active Early Stage Drug Developers….

with 1400+ Early Stage Active Molecules, Target, Tech. Deals and management contact details.

REPORT PROVIDES LARGEST COVERAGE – GURANTEED

Further Details & Download Preview Copy :- https://omicsx.com/reports/cancer/global-oncology-preclinical-drug-intelligence-2022/

For Social Newsletter based on this Report – https://www.linkedin.com/newsletters/oncology-drug-developers-6937698358589288449/

Virendra Singhvi
OmicsX
+91 97602 41412
info@omicsx.com





Source link

RELATED ARTICLES

Most Popular